Innate Pharma has dosed the first patient in a Phase I trial of its antibody-drug conjugate (ADC), IPH4502, which is designed to target tumours expressing Nectin-4. The Marseille, France-based company ...

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of Nectin-4-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering. This competitive intelligence report about ...

Nectin-4 has been successfully established as a target molecule in locally advanced and metastatic bladder cancer. An antibody-drug conjugate (enfortumab-vedotin) directed against nectin-4 has shown ...

Corbus Pharmaceuticals Holdings (CRBP) announced the appointment of Leonardo Viana Nicacio as Chief Medical Officer. Nicacio brings over 20 years of pharmaceutical and oncology experience, notably ...

First-in-class antibody-drug conjugate (ADC) that targets Nectin-4, which is a cell surface protein highly expressed in bladder cancer. Preclinical data suggest that the anticancer activity of it is ...

SAN DIEGO, May 6, 2025 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life ...

SHANGHAI, April 21, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industrial chain, announced that a recent clinical case report on ...

Q3W schedule of CRB-701 (SYS6002) demonstrates a 43% ORR and 71% DCR at predicted therapeutically relevant doses All assessable nectin-4 positive study participants with mUC and cervical cancer ...

Combination cohort initiated following successful review of monotherapy cohort Over 100 participants dosed to-date in monotherapy cohort Priority are Head and Neck Squamous Cell Carcinoma (HNSCC) and ...

A systematic literature review was performed on March 2023 using PubMed, MEDLINE, and Embase databases according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.

“ In this study, we aimed to determine the rate of Nectin-4 positivity in a contemporary cohort of HNSCC and to correlate these findings with clinico-pathological parameters.” Nectin-4 has been ...